"Medicare patients should not become the testing ground for cannabinoid products that have not undergone the rigorous FDA drug development process required to establish safety, efficacy, manufacturing consistency and appropriate dosing," says Duane Boise CEO of MMJ International Holdings.
Dr. Oz's Push to Expand Medicare CBD Access After European Regulators Could Not Establish Safety of Charlotte's Web Hemp Extract
